Crinetics Pharmaceuticals (NASDAQ: CRNX) reported Q1 EPS of ($1.23), $0.05 better than the analyst estimate of ($1.28). Revenue for the quarter came in at $10.7 million versus the consensus estimate of $8.51 million.

For earnings history and earnings-related data on Crinetics Pharmaceuticals (CRNX) click here.